Tai Chen

Tai Chen is the Head of Japan Development at GSK, where they serve as a thought leader and innovator in the field of global drug development. With over 22 years of experience, Tai specializes in biostatistics, clinical pharmacology, and organizational building across various therapeutic areas, including oncology and hematology. Among their notable achievements, Tai was the statistical leader for the first checkpoint inhibitor, ipilimumab, and has contributed significantly to the development of methodologies in immuno-oncology. Previously, Tai held various leadership positions at Bristol Myers Squibb and served as an adjunct assistant professor at Columbia University, establishing a graduate curriculum in pharmaceutical statistics.